Bottom line
Is TGFRX a good fund? The bottom line
TGFRX is an actively managed large growth mutual fund from Tanaka.
Its expense ratio is 1.95% — about $195 a year on every $10,000 invested, more expensive than 97% of large growth funds we track.
It returned +39.3% over one year, +19.4% a year over five years, +12.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $39.7 million in net assets and 25 holdings, its largest position is Corcept Therapeutics, Inc. (9.1%) and the top 10 make up 58.5% of the portfolio.
What stands out
- 5-year return beat 99% of category peers
What to watch
- Expensive for its category (1.95%)
- Concentrated: top 10 holdings are 58.5% of assets
- 12b-1 marketing fee of 0.25% a year
- Small fund ($39.7 million) — small funds are likelier to close
Updated Nov 19, 2026
What TGFRX invests in
The Fund's investment objective is growth of capital.
The Fund employs the following principal investment strategies: Normally investing in common stocks and other equity securities of small, medium and large capitalization companies. Investing up to 45% of its net assets, measured at the time of investment, in foreign securities, including multinational and emerging market securities. The Fund is a non-diversified fund, which means that the Fund may take larger positions in a small number of companies than a diversified fund. Investing in issues which the Fund's investment Advisor believes have superior capital growth potential. Companies that meet or exceed specific criteria established by the investment manager in the selection process are purchased. Securities are sold when they reach internally determined pricing targets or no longer qualify under the managers investment criteria. While the Fund usually will normally diversify its…
From the fund's prospectus (filed Mar 31, 2026).
TGFRX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| TGFRX | +39.3% | +19.4% | +12.8% |
| Large Growth median | +15.2% | +11.0% | +14.2% |
Source: Fund prospectus, as of Dec 31, 2025
What TGFRX costs
On a $10,000 investment, TGFRX's 1.95% expense ratio costs about $195 a year. The prospectus estimates $2,275 in total costs over 10 years (assuming 5% annual returns). The median large growth fund charges 0.87%.
TGFRX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Corcept Therapeutics, Inc. | 9.14% |
| 2 | NVIDIA Corp. | 7.41% |
| 3 | United States Antimony Corp. | 7.34% |
| 4 | Nuvation Bio, Inc. | 5.83% |
| 5 | NexGen Energy Ltd. | 5.54% |
| 6 | Aura Minerals, Inc. | 5.49% |
| 7 | Apple, Inc. | 5.15% |
| 8 | Intellia Therapeutics, Inc. | 4.39% |
| 9 | Applied Materials, Inc. | 4.38% |
| 10 | Electrovaya, Inc. | 3.82% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 58.5% of the fund. See all top 25 holdings and asset mix →